Device Performance

ZyMōt Fertility Inc., has developed novel devices for use in ART procedures conducted by fertility clinics and OB/GYN practices. ZyMōt Multi Sperm Separation Devices prepare motile sperm from semen for use in IUI and ICSI procedures. These FDA-cleared, CE-certified devices are the first of their kind and available worldwide.

DxNow has developed novel devices for use in ART procedures
conducted by fertility clinics and OB/GYN practices.

Building on research from Parrella et al in 20191 ,scientists at Weill-Cornell Medical College have been examining various impacts of genomic integrity. Specifically, these Weill-Cornell researchers have studied sperm chromatin fragmentation (SCF) and the effects on clinical outcomes.

To assess the role of an enhanced sperm selection method in mitigating paternal contributions to embryo aneuploidy.

Processing sperm with ZyMōt devices improved patients’ IUI treatment prognosis, when compared to DGC processing. In a study of 265 patients, evenly split between traditional, DGC processing and ZyMōt-processed groups, ZyMōt use significantly improved the ongoing clinical pregnancy rate by almost 10%.